Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Shares Outstanding (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Shares Outstanding for 14 consecutive years, with $7000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 99.97% to $7000.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $7000.0, a 99.97% decrease, with the full-year FY2025 number at $21.7 million, up 147872.79% from a year prior.
  • Shares Outstanding was $7000.0 for Q4 2025 at PharmaCyte Biotech, down from $21.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $21.7 million in Q4 2024 to a low of -$12.9 million in Q3 2023.
  • A 5-year average of $12.1 million and a median of $20.7 million in 2022 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: crashed 525.12% in 2023, then skyrocketed 367472.85% in 2025.
  • PharmaCyte Biotech's Shares Outstanding stood at $20.7 million in 2021, then plummeted by 110.02% to -$2.1 million in 2022, then plummeted by 525.12% to -$13.0 million in 2023, then soared by 267.07% to $21.7 million in 2024, then plummeted by 99.97% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Shares Outstanding are $7000.0 (Q4 2025), $21.7 million (Q3 2025), and $21.7 million (Q1 2025).